跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SIGNIFOR LAR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SIGNIFOR LAR
Authorized
STANDARD
SIGNIFOR LAR
recordati rare diseases canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ed850c557b0fe5dc
Company
recordati rare diseases canada inc
Type
Standard
Approval Details
Approval Id
ed850c557b0fe5dc
Drug Approval Canada Name
SIGNIFOR LAR
Product Name
SIGNIFOR LAR
Status
Marketed
Status Date
2020-05-21
Original Market Date
2019-05-30
Din
02480425
Drug Class
Human
Dosage Form
Powder For Suspension, Sustained-Release , Kit
Route Of Administration
Intramuscular
Schedule
Prescription
Ahfs
68:29.04
Atc Original
H01CB05 PASIREOTIDE
Atc Name
h 01 cb 05
Aig Number
0154790007
Company Name
recordati rare diseases canada inc
Company Address
3080 Yonge Street, Suite 6060, Toronto, Ontario, Canada, M4N 3N1
Active Ingredients
PASIREOTIDE (PASIREOTIDE PAMOATE)
10 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ed850c557b0fe5dc
Type
Standard
Back to Health Canada Approvals